Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)

PFE 24.65

+1.5%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zyx1996 who wrote (1646)	2/25/2000 9:19:00 PM
From: runningelk	Read Replies (3) of 1722

BMY and JNJ could almost be considered Biotech but with a conservative valuation. JNJ purchased Centacor recently, greatly increasing their pipeline potential of cutting edge drugs. The potential of this, like most biotechs, is years out, but they have real products coming out that should only propel earnings and growth. BMY is in a race to develop the next Taxol cancer drug, and looks like it will win with its research. This could be another blockbuster for them and we should be hearing soon. The only biotech that interests me and that I own is Amgen with 2 potential blockbusters on the way by year end. I am also putting my kids into this one on any dip. Stay in touch. Runningelk

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next